QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
April 16, 2024 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and...
QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma
August 18, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...
QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
August 11, 2021 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the...
QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
February 16, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...